A Phase 3b Study of 2 Treatment Durations of Telaprevir, Peg-IFN (Pegasys), and Ribavirin (Copegus) in Treatment-Naive and Prior Relapser Subjects With Genotype 1 Chronic Hepatitis C and IL28B CC Genotype.

Trial Profile

A Phase 3b Study of 2 Treatment Durations of Telaprevir, Peg-IFN (Pegasys), and Ribavirin (Copegus) in Treatment-Naive and Prior Relapser Subjects With Genotype 1 Chronic Hepatitis C and IL28B CC Genotype.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 30 Nov 2015

At a glance

  • Drugs Telaprevir (Primary) ; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C
  • Focus Registrational; Therapeutic Use
  • Acronyms CONCISE
  • Sponsors Vertex Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 26 Jan 2015 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
    • 26 Feb 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top